BTK Inhibitor Compounds Overcoming Resistance via Cys481 Binding

The patent modifies the chemical structure of BTK inhibitors by changing parameters such as the warhead group (electrophilic moiety), linker length and composition (L1-L6), and heterocyclic ring substitutions (Q0-Q4). These parameter changes create novel compounds with improved potency and selectivity that can overcome resistance mechanisms developed against first-generation inhibitors like ibrutinib.

The patent employs composite molecular structures combining multiple functional elements: a warhead group for covalent binding to Cys481, linker regions (L1-L6) for optimal positioning, and heterocyclic cores (Q0-Q4) for binding affinity. This composite approach creates inhibitors with enhanced properties that address resistance issues while maintaining target engagement.

The patent applies local quality by optimizing specific regions of the inhibitor molecule: the warhead group is designed for selective covalent interaction with Cys481, while the linker and heterocyclic portions are tuned for selective binding to the BTK kinase domain. This localized optimization ensures high potency at the target site while minimizing off-target effects and resistance development.

The patent uses the BTK kinase domain itself as an intermediary, designing inhibitors that exploit the enzyme's active site architecture and catalytic mechanism. By targeting the ATP-binding pocket and forming covalent bonds with the catalytic cysteine (Cys481), the inhibitors achieve selective inhibition that spares other kinases and overcomes resistance through mechanism-based specificity.